Cresco Labs: Analyst Q4 2020 Consensus Expectations
Cresco Labs (CSE: CL) announced that they will be reporting their fourth quarter and year-end financials pre-market on March 25th. Analysts have a consensus C$22.22 12-month price target on the company, via a total of 16 analysts, with four analysts having a strong buy rating and the other 11 have buy ratings and one analyst has a hold rating. The street high comes from Stifel-GMP with a C$36 price target, and the lowest target comes from Roth Capital with a C$17.50 price target.
Sixteen analysts have revenue estimates for the fourth quarter. The mean between all 16 is U$161.38 million; this number has been revised downwards from U$162.50 million at the start of the year. Needham & Co currently has the highest revenue estimate with U$167.8 million, while the lowest comes from Piper Sandler with a U$156.1 million estimate.
For the full year, the average revenue estimate between 16 analysts is currently U$475.52 million. This number has been revised downwards from U$475.52 million at the start of the year. The street high comes from Needham & Co with a U$481.70 full-year revenue estimate, while the lowest comes from Piper Sandler with a U$470 million estimate.
Onto EBITDA estimates, there are currently 14 analysts who have fourth-quarter EBITDA estimates. The mean is currently U$48.06 million, with this number roughly the same since the start of the year. Street high goes to Needham & Co with a U$52,14 million EBITDA estimate and the lowest being ATB Capital with a U$42.20 million estimate.
For the full year, the current EBITDA mean across 12 analysts is U$114.13 million. This number is roughly the same since the start of the year. Needham & Co currently has the highest full-year estimate at U$118.21 million and the lowest being Benchmark with a U$158 million estimate.
Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
